May 16, 2019
4D pharma’s Chron’s treating Thetanix meets objective
4D pharma’s study of Thetanix for treating Crohn’s disease has met primary objective, as it showed Thetanix was well tolerated with a good safety profile.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
May 16, 2019
ChargePoint Technology boosts UK presence with new appointment
Contained and sterile transfer solutions expert, ChargePoint Technology, has appointed Stephen Eastick as UK Sales Manager.
May 13, 2019
Celgene’s Pomalyst gets breakthrough therapy amrk from FDA for HIV-Positive and Negative Kaposi Sarcoma
Celgene plans additional studies with the AIDS Malignancy Consortiumin U.S. and sub-Saharan Africa
May 13, 2019
Sesen meets with FDA over Vista in May and June
Sesen bio to use the most recent analysis of its 12-monthPhase 3 VISTA trial data, which will be the basis for the meetings withthe FDA in May and June.
May 13, 2019
R&D in the biopharmaceutical industry is witnessing an upsurge
The traditional R&D in the biopharmaceutical industry iswitnessing an upsurge, due to drug development research, which ishelping in the augmentation of the industrial microbiology market.
May 13, 2019
Acerus first quarter 2019 revenue 33% up from last year’s same period
Acerus posts total revenues in Q1-2019 of $2.2 million, an increase of $0.5 millionor 33% compared to the first quarter of 2018 (“Q1-2018”).
May 13, 2019
Lilly gets fifth FDA approval for Cyramza
Eli Lilly’s Cyramza got its fifth FDA approval for in an advanced or metastatic cancer – this one for the second-line treatment of patients with hepatocellular carcinoma (HCC) who are AFP-High (AFP ≥400 ng/mL).
May 13, 2019
North America expected to provide high business for the atopicdermatitis market 2019-2024
Food allergy has been essentially highly debatable for decades in atopicdermatitis, with some common food, including milk, egg, and soy. Thereis a lot of literature which provides evidence that common foodexacerbate atopic dermatitis.
May 13, 2019
Medivir has positive data from basal cell carcinoma study
Swedish Medivir said Monday that positive data from the investigator-initiated study of remetinostat in basal cell carcinoma (BCC) patients has shown that remetinostat gel offers a potentially effective and well-tolerated, non-surgical intervention for treatment of localized BCCs.
May 13, 2019
Transgene gets FDA IND clearance to start clinical trial of myvac for ovarian cancer treatment
Transgene can start linical trial of its lead myvac™ candidate TG4050as a potential treatment for ovarian cancer patients after first-linesurgery and chemotherapy